The Global Health Body Issues Alert Over Critical Lack of Obesity Medications

Less than a tenth of patients who could benefit from obesity jabs like Wegovy can access them, warns the global health agency as it publishes its first advice on the therapies.

Considering more than one billion individuals worldwide now living with obesity, it is urging increased and just access to this class of drugs.

Based on estimates, in excess of 2,000,000,000 will be obese by 2030 without intervention.

"The new guidance acknowledges that obesity is a lifelong illness that can be addressed with comprehensive and continuous support," said its chief Tedros Adhanom Ghebreyesus.

Significant expense, limited production capacity, and logistical bottlenecks are major obstacles to broad availability to the injections that can assist patients in reducing significant weight, explains the body.

Weight-Loss Drug Supply Crisis

Even in the present most favorable scenario, the production of GLP-1 therapies might only reach about 100 million people – less than 10% of those who need them, as stated by the WHO.

The recommendation urges countries and companies to expand access, through strategies like voluntary licensing.

Exclusive production rights on the active ingredient – the primary component of a leading brand – is set to lapse in multiple nations in 2026.

How Obesity Drugs Operate

GLP-1 drugs mimick a body's own hormone to reduce digestion speed, reduce hunger and boost satiety so users reduce food intake.

Patients commonly see weight reduction within a few weeks of commencing the once-weekly jabs.

Evidence points to people may put most of the weight back on within a year of halting the medication, as their usual appetite resume.

To be carrying excess weight raises your likelihood for developing diseases, like type 2 diabetes, cardiovascular issues, brain attack, and certain malignancies.

Excess weight concerns people in all nations and was responsible for millions of deaths worldwide in 2024, as per the WHO.